CV:ATE Antibe Therapeutics Inc.

Antibe Therapeutics, Inc. is a biotechnology company, which engages in the development of medicines for pain and inflammation. It operates through the Antibe Therapeutics, and Citagenix segments. The Antibe Therapeutics segment focuses on the development of pharmaceutical products. The Citagenix segment involves in the development and sale of regenerative medicines serving the dental and orthopedic market places. The company was founded by Andre Buret, John Wallace and Giuseppe Cirino on May 5, 2009 and is headquartered in Toronto, Canada.

This company cross-lists their shares on a U.S. stock exchange. See the related U.S. symbol ATBPF.

0.41 CAD
As of 11/11/2020


Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Developed markets ex-US
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Canada
Country of incorporation:  Canada
IPO date:  01/01/1900
Stock exchange:    TSX Venture Exchange
Exchange country:   Canada
Market cap:   148,402,880 CAD
Current dividend yield:   0.00%
CUSIP:    
ISIN:        CA0370251039
Sedol:      

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy